Dermira, Inc.
275 Middlefield Road
Suite 150
Menlo Park
California
94025
United States
Tel: (650) 421-7200
Fax: 650-365-3410
Website: http://www.dermira.com/
Email: info@dermira.com
112 articles about Dermira, Inc.
-
Eli Lilly and Company is set to cut 163 jobs as it closes its Dermira facility in Menlo Park and sells off the latter company’s sweat drug Qbrexza, which is being snatched up by Journey Medical.
-
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
4/1/2021
Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into a definitive agreement to acquire QBREXZA (glycopyrronium) in the U.S. from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company.
-
Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and Company
1/7/2021
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced it has entered into an exclusive license agreement with Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, to develop and commercialize three development programs for the treatment of various inflammatory disea
-
Lilly Completes Acquisition of Dermira
2/20/2020
INDIANAPOLIS , Feb. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Ph
-
(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?
1/10/2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company..
-
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion.
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec. 10, 2019
12/10/2019
Dermira, Inc. announced that on December 9, 2019, the company granted inducement awards to 11 new employees.
-
Dermira to Participate in December Investor Conferences
11/27/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in two investor conferences in December.
-
Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference
11/14/2019
New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab’s role in inhibiting itch signals in atopic dermatitis
-
Dermira Elects Halley E. Gilbert to its Board of Directors
11/13/2019
Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced the election of Halley E. Gilbert to its board of directors.
-
Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day
11/11/2019
Dermira, Inc. announced that company management will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day on Monday, November 18, 2019 at 9:00 a.m. ET in New York, NY.
-
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/5/2019
Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis
-
Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019
10/29/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended September 30, 2019 and provide an operational update after market close on Tuesday, November 5, 2019.
-
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
10/17/2019
Lebrikizumab demonstrated dose-dependent improvements across endpoints spanning the range of atopic dermatitis signs and symptoms, including skin lesions and pruritus, when administered once every two or four weeks
-
Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
10/10/2019
Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference
-
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
10/9/2019
Two identical Phase 3 monotherapy studies expected to enroll a total of approximately 800 adult and adolescent patients ages 12 and older
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 8, 2019
10/8/2019
Dermira, Inc. announced that on October 7, 2019, the company granted inducement awards to 12 new employees.
-
Dermira to Participate in the 2019 Cantor Global Healthcare Conference
9/26/2019
Dermira, Inc. announced that company management will participate in the 2019 Cantor Global Healthcare Conference taking place October 2-4, 2019 in New York, NY.
-
Dermira to Participate in Upcoming Investor Conferences
8/29/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that the company will participate in two investor conferences in September.
-
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
8/7/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended June 30, 2019 and provided a corporate update.